This research explores how mast cells—immune cells responsible for allergy symptoms—can be repurposed to strengthen vaccines. By targeting mast cells with nasal vaccines, stronger and longer-lasting immune responses may be generated, particularly benefiting high-risk populations and improving protection against infectious diseases.

Malaria infects hundreds of millions each year by using the parasite Plasmodium to invade the liver through the CSP protein. This research designs tightly binding antibodies to block infection at its earliest stage, improving vaccine effectiveness and offering a path toward preventing malaria before symptoms begin.